News Story: Full Text
Sponsored By
Cedars-Sinai Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website


Trabectedin has promising antineoplastic activity in high-grade meningioma.

Al's Comment:

 Way too early - and had significant side effects in the 1 person they tried it on, but may be an option for people with high grade meningioma who run out of other options.  It is available off label now under the brand name Yondelis

Posted on: 11/25/2012

Trabectedin has promising antineoplastic activity in high-grade meningioma.

Cancer.  2012; 118(20):5038-49 (ISSN: 1097-0142)


Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W

Department of Medicine I, Medical University of Vienna, Vienna, Austria; Comprehensive Cancer Center-Central Nervous System Tumors Unit, Medical University of Vienna, Vienna, Austria.


BACKGROUND: Meningiomas are common intracranial tumors arising from the meninges and usually are benign. However, a few meningiomas have aggressive behavior and, for such patients, effective treatment options are needed. Trabectedin is a novel, marine-derived, antineoplastic agent that has been approved and is used routinely as therapy for advanced soft tissue sarcoma and ovarian cancer.


METHODS: The authors investigated the in vitro effects of trabectedin alone and in combination with hydroxyurea, cisplatin, and doxorubicin in primary cell cultures of benign (n = 9), atypical (n = 6), and anaplastic (n = 4) meningiomas using chemosensitivity assays (3-[4,5dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide [MTT]), Western blot analysis, cell cycle analysis, and immunofluorescent staining.


RESULTS: Strong antimeningioma activity of trabectedin was observed and was characterized by distinct cell cycle arrest, down-regulation of multiple cyclins, deregulated expression of cell death-regulatory genes, and massive apoptosis induction. Cytotoxic activity was especially intense in higher grade meningiomas with a half-maximal inhibitory concentration <10 nM. Combination with trabectedin synergistically enhanced the antimeningioma activity of hydroxyurea but also enhanced the activity of doxorubicin and cisplatin. On the basis of these findings, trabectedin was given to 1 patient who had heavily pretreated, anaplastic meningioma, and a favorable response was observed with radiologic disease stabilization, marked reductions in brain edema and requirement for corticosteroids, and improvement of clinical symptoms. However, treatment had to be discontinued after 5 cycles because of adverse drug effects.


CONCLUSIONS: The current results indicated that trabectedin may represent a promising new therapeutic option for patients with aggressive meningioma and should be evaluated in prospective clinical studies. Cancer 2012. © 2012 American Cancer Society.


Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557